Pierre Fabre Medicament

This study tested a new two-drug combination (encorafenib plus cetuximab) against standard treatments in 107 Chinese patients with a specific genetic mutation (BRAF V600E) causing metastatic colorectal cancer. The goal was to see if the new combo could slow cancer growth better t…

This study measured how skin problems caused by hormone therapy impact the daily lives of women with early breast cancer. Researchers surveyed 155 women from several European countries who had been on hormone therapy for 2-3 years. The women completed questionnaires about their s…

This study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received neratinib as an extra treatment after their initial therapy. The goal was to describe the patients' characteristics, such as age, tumor details, and health history. It did …

This study looked back at medical records of 274 people with a specific genetic mutation (BRAF V600E) in advanced colorectal cancer. The goal was to see which treatments doctors actually used and how well they worked in everyday practice. No new treatments were tested; instead, r…

This study observed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, and their quality of life. No new t…